UTMB Incident Command met on Jan. 10, 2022, to discuss the latest information related to the omicron variant and UTMB's response. Read the update.

UTMB Incident Command met on Jan. 7, 2022, to discuss the latest information and UTMB's response to the omicron variant.

El 3 de enero de 2022, la Administración de Alimentos y Medicamentos (FDA, en inglés) enmendó la autorización de uso de emergencia (EUA, en inglés) de la vacuna antiCOVID-19 de Pfizer-BioNTech para expandir el uso de una sola dosis de refuerzo en adolescentes entre 12 y 15 años de edad. El 5 de enero, los Centros para el Control y la Prevención de Enfermedades (CDC, en inglés) también actualizaron sus recomendaciones relacionadas.

On Jan. 3, 2022, the U.S. Food and Drug Administration amended the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine to expand the use of a single booster dose to adolescents aged 12 through 15 years old. Click the headline to read more.

From the COVID-19 Clinical Task Force: Antigen testing required on Day 5 for employees and students with patient care responsibilities; self-scheduling of antigen test now available for these individuals; requirements for non-health-care individuals updated.

UTMB Incident Command met on Dec. 31, 2021, to discuss the continuing increase in COVID-19 cases due to the omicron variant.

CDC Interim Guidelines designed to ensure adequate health care workforce during surge of omicron variant; updated return-on-site policies for UTMB health care workers take effect Dec. 28, 2021

As a result of a rapid increase of the COVID-19 Omicron variant in our community, pre-procedure COVID testing requirements have been modified (effective 12/22/2021).

As a result of a rapid increase of the COVID-19 Omicron variant in our community, pre-procedure COVID testing requirements have been modified (effective 12/22/2021).

Over the past weeks there have been new developments to the ongoing COVID-19 pandemic. A new message from the COVID-19 Clinical Task Force provides additional details on the Omicron variant, COVID boosters and flu vaccinations.

Pfizer-BioNTech Boosters have now been approved for all 16 years of age and older, regardless of risk factors. Adolescents 16 and 17 years old who received a Pfizer-BioNTech COVID-19 vaccine are eligible for a booster shot at least six months after completion of their primary series.

Adults 18 and older who received a Moderna or Pfizer-BioNTech COVID-19 vaccine are now eligible for a booster shot at least six months after completion of their primary series.

Vaccine boosters have now been approved for all adults 18 years of age and older, regardless of risk factors. Those who received a Moderna or Pfizer-BioNTech COVID-19 vaccine are eligible for a booster shot at least six months after completion of their primary series. For Johnson & Johnson/Janssen single-dose vaccine recipients, a booster is available after two months.

UTMB Incident Command met on Jan. 10, 2022, to discuss the latest information related to the omicron variant and UTMB's response. Read the update.

UTMB Incident Command met on Jan. 7, 2022, to discuss the latest information and UTMB's response to the omicron variant.

El 3 de enero de 2022, la Administración de Alimentos y Medicamentos (FDA, en inglés) enmendó la autorización de uso de emergencia (EUA, en inglés) de la vacuna antiCOVID-19 de Pfizer-BioNTech para expandir el uso de una sola dosis de refuerzo en adolescentes entre 12 y 15 años de edad. El 5 de enero, los Centros para el Control y la Prevención de Enfermedades (CDC, en inglés) también actualizaron sus recomendaciones relacionadas.

On Jan. 3, 2022, the U.S. Food and Drug Administration amended the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine to expand the use of a single booster dose to adolescents aged 12 through 15 years old. Click the headline to read more.

From the COVID-19 Clinical Task Force: Antigen testing required on Day 5 for employees and students with patient care responsibilities; self-scheduling of antigen test now available for these individuals; requirements for non-health-care individuals updated.

UTMB Incident Command met on Dec. 31, 2021, to discuss the continuing increase in COVID-19 cases due to the omicron variant.

CDC Interim Guidelines designed to ensure adequate health care workforce during surge of omicron variant; updated return-on-site policies for UTMB health care workers take effect Dec. 28, 2021

As a result of a rapid increase of the COVID-19 Omicron variant in our community, pre-procedure COVID testing requirements have been modified (effective 12/22/2021).

As a result of a rapid increase of the COVID-19 Omicron variant in our community, pre-procedure COVID testing requirements have been modified (effective 12/22/2021).

Over the past weeks there have been new developments to the ongoing COVID-19 pandemic. A new message from the COVID-19 Clinical Task Force provides additional details on the Omicron variant, COVID boosters and flu vaccinations.

Pfizer-BioNTech Boosters have now been approved for all 16 years of age and older, regardless of risk factors. Adolescents 16 and 17 years old who received a Pfizer-BioNTech COVID-19 vaccine are eligible for a booster shot at least six months after completion of their primary series.

Adults 18 and older who received a Moderna or Pfizer-BioNTech COVID-19 vaccine are now eligible for a booster shot at least six months after completion of their primary series.

Vaccine boosters have now been approved for all adults 18 years of age and older, regardless of risk factors. Those who received a Moderna or Pfizer-BioNTech COVID-19 vaccine are eligible for a booster shot at least six months after completion of their primary series. For Johnson & Johnson/Janssen single-dose vaccine recipients, a booster is available after two months.